The Investment Management Agency of Daya Anagata Nusantara (Danantara Indonesia) has signed a Memorandum of Understanding (MoU) with South Korea’s SK Plasma Co. Ltd, a global leader in plasma-derived medicinal products (PDMPs) for rare and critical conditions, and its Indonesian subsidiary, PT SK Plasma Core Indonesia. This partnership represents a strategic move to bolster Indonesia’s health resilience by reducing import dependency and advancing self-sufficiency in healthcare services.
Danantara Indonesia’s Chief Investment Officer emphasized that strengthening national resilience in critical sectors such as healthcare is one of the company’s key investment priorities. He explained that the collaboration between SK Plasma’s technical expertise and Danantara’s strategic investment seeks to enhance the quality of patient care and save lives through innovative, globally standardized therapies. He added that the signing of this MoU marks a significant milestone in advancing efforts toward a healthier and more resilient Indonesia.
As part of its 2025 investment strategy, Danantara has identified healthcare as one of its eight priority sectors, with plans to develop blood plasma facilities and strengthen national health infrastructure.
SK Plasma’s CEO expressed gratitude for the collaboration, noting that it is an honor for the company to help strengthen Indonesia’s healthcare system. Drawing on its expertise in PDMPs, SK Plasma remains committed to partnering with countries seeking to localize essential medicines and to advancing global healthcare infrastructure.
The partnership with Danantara is expected to strengthen Indonesia’s efforts to achieve self-sufficiency in plasma-derived medicines while creating employment opportunities for skilled professionals in biotechnology and pharmaceuticals. Additionally, the company has committed to facilitating knowledge transfer by providing training programs for Indonesian workers at its South Korean facilities.
PDMPs are therapies produced from human plasma through a process called fractionation. They are essential in treating severe and often life-threatening conditions for which patients have limited treatment options. To date, Indonesia has relied entirely on imported PDMPs, leaving its supply chain vulnerable to global disruptions.
In response, Danantara and SK Plasma will strengthen Indonesia’s local manufacturing capabilities by establishing a plasma derivative production facility in Karawang, West Java, targeted for completion by 2026. Danantara believes that a strong and self-sustaining healthcare system is essential for driving national economic growth, as investments in this sector enhance productivity while lowering healthcare costs for millions. Over the next year, the company will concentrate its efforts on three strategic areas: healthcare services, manufacturing, and innovation.
Through its subsidiary, PT SK Plasma Core Indonesia, SK Plasma is building a plasma fractionation facility that will enable local production of PDMPs. The project aims to reduce import dependency while promoting technology transfer and the development of a skilled local workforce. Following the signing, both parties will continue to explore additional investment opportunities and will share further details in due course, subject to due diligence and compliance with applicable legal requirements.
(Source: ANTARA News)
